Esperavir
| LP-007856 | |
| Name | Esperavir |
| Dosage form | Capsules |
| Nosological classification | J05AX27 |
| INN | Molnupiravir |
| Active agent | Formula, per capsule: Active ingredient: Excipients: Povidone K30 Sodium stearyl fumarate Capsule body: Gelatin Capsule cap: Titanium dioxide (E171) Gelatin |
Esperavir inhibits the reproduction of RNA viruses, exerts its antiviral effect by introducing errors during viral RNA copying:
after 5 days of therapy, the virus is completely eliminated from the body, and recovery is achieved in 9 out of 10 patients;
after 3 days of therapy, catarrhal-febrile syndrome disappears in 70% of patients.
In a pandemic, even if the test for COVID-19 is negative, which is quite common for infection with the Omicron strain, the use of Esperavir is reasonable to prevent the disease progression and minimize the risk and severity of post-COVID syndrome.
The drug is used2 400 mg twice daily by prescription of a doctor. Treatment should be started no later than the 5th day from the onset of the disease. The duration of treatment is 5 days.
An open, two-stage, multicenter study to evaluate the main pharmacokinetic parameters, safety, and efficacy against COVID-19 of Esperavir (molnupiravir) in capsules (Promomed RUS LLC, Russia) in adult population.
Prescription product. Consult a doctor before use.
